Bristol-Myers Squibb’s Opdivo and Yervoy Combo Fails in Phase III Trial
Bristol-Myers Squibb has reported that their Opdivo and Yervoy checkpoint inhibitor combo failed a phase III trial as adjuvant (post-surgery) therapy for renal cell carcinoma (RCC), the most frequent type of kidney cancer. The CheckMate -914 trial's disappointing results weaken BMS' expectations of moving PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab) treatment into earlier-stage malignancies.
Opdivo/Yervoy has been approved as a first-line treatment for patients with intermediate- and poor-risk advanced RCC since 2018, and BMS hoped to expand its use into patients...
